Given our observation that RAS upregulation in response to BRAFi/MEKi in glioma is associated with a rebound in pERK activity and contributes to limited response duration to BRAFi or MEKi, we postulated that inhibition of SHP2, a critical regulator of RAS activity, might prevent adaptive resistance. Here, PTPN11 is linked to central nervous system cancer.